Asco 2021 – Bristol makes more progress in stomach cancer
But the space, a battle between Opdivo and Keytruda, is becoming extremely complex, and Bristol’s win is not unequivocal.
Asco 2021 – full Olympia results sweep away Parp doubts
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Zolgensma flatlines, but Spinraza isn’t the beneficiary
A fiercely competitive three-horse race in spinal muscular atrophy is Evrysdi’s for the taking.
